INNOVATE Corp (VATE) announced that its subsidiary MediBeacon’s transdermal glomerular filtration rate (tGFR) technology article was recognized as a 2025 Editors’ Choice by the Journal of the American Society of Nephrology. The TGFR System is now being clinically deployed in centers of excellence aimed at improving kidney function measurement for various medical applications. This recognition and deployment could establish MediBeacon’s technology as a new standard of care, bolstering INNOVATE’s position in the life sciences sector.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
INNOVATE Highlights MediBeacon Kidney Function Technology Recognition
INNOVATE Corp (VATE) announced that its subsidiary MediBeacon’s transdermal glomerular filtration rate (tGFR) technology article was recognized as a 2025 Editors’ Choice by the Journal of the American Society of Nephrology. The TGFR System is now being clinically deployed in centers of excellence aimed at improving kidney function measurement for various medical applications. This recognition and deployment could establish MediBeacon’s technology as a new standard of care, bolstering INNOVATE’s position in the life sciences sector.